Navigation Links
Vasogen to Conduct Year-end 2007 Conference Call
Date:1/11/2008

tal on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a
'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
2. Vasogen Provides an Update on ACCLAIM-II Preparations
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Announces Third Quarter 2007 Results
5. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
6. Hybrid semiconductors show zero thermal expansion; Could lead to hardier electronics
7. Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease
8. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
9. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
10. Doping technique brings nanomechanical devices into the semiconductor world
11. IBM and Imago find a crucial difficulty in semiconductor device scaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 2014 Deep ... is a professional and in-depth study on the current ... China. , The report provides a basic overview of ... Global market analysis and Chinese domestic market analysis are ... competitive landscape of the market. A comparison between the ...
(Date:7/12/2014)... 2014 This report covers ... in the life science industry. Continuous innovation ... reagents market towards remarkable growth. The stakeholders ... of life science reagents. , Brows full ... . , The global life science reagents ...
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2
... ... ... ... , ...
... ... for different body types and shampoo bottles shaped to closely match the size of ... to redesign armor for troops in Afghanistan. , ... Madison, NJ, USA (PRWEB) February 24, 2010 -- Interactive exhibits make learning ...
... ... ... , ... , , , , ...
Cached Biology Technology:Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 2Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 3Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 4Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 5Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 6Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 7Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 2Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... A new neuroimaging study conducted by researchers from the ... de Montral at the International laboratory for Brain Music ... amusic individuals have more grey matter in specific regions ... the right interior frontal gyrus and the right auditory ...
... Approximately one in every 500 to 650 baby boys is ... genetic code that until a few years ago was thought ... no longer the case. A recent conference hosted by NewYork-Presbyterian ... raising awareness of the condition and the recent availability of ...
... chew up rattlesnake skin and smear it on their ... a new study by researchers at UC Davis. ... UC Davis, observed ground squirrels (Spermophilus beecheyi) and rock ... picking up pieces of shed snakeskin, chewing it and ...
Cached Biology News:Jingle bells not merry for tone-deaf individuals 2Jingle bells not merry for tone-deaf individuals 3Physician-scientists seek solutions to reproductive problems related to chromosomal variations 2Physician-scientists seek solutions to reproductive problems related to chromosomal variations 3
...
...
...
... Streptavidin Sepharose High Performance, 5 ... media used in HiTrap Streptavidin columns ... compounds.Ideal for packing into Tricorn 5/50 ... when larger scale purifications are required.Extremely ...
Biology Products: